Copyright
©The Author(s) 2021.
World J Clin Oncol. Jan 24, 2021; 12(1): 31-42
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.31
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.31
Table 2 Priorities of outpatient visits for breast cancer during the coronavirus disease 2019 pandemic
High priority | Medium priority | Comments |
(1) Unstable postsurgical patients (hematoma, infection, bleeding) (Yes: 100%, No: 0%); (2) Oncological emergencies (febrile neutropenia, uncontrolled pain, symptomatic brain metastases) (Yes: 100%, No: 0%); (3) BC diagnosis during pregnancy (Yes: 100%, No: 0%); and (4) De novo locally advanced BC with aggressive phenotypes (HER2, TNBC) (Yes: 78%, No: 22%) | (1) De novo invasive BC (during the multidisciplinary evaluation, priority is guided by tumor biology and clinical stage) (Yes: 89%, No: 11%); (2) Intercurrences on-treatment patients (new signs/symptoms, abnormal findings during physical examination, adverse events (Yes: 100%, No: 0%); (3) Patients on active intravenous chemotherapy (Yes: 78%, No: 22%); and (4) Stable routine postsurgical patients (Yes: 100%, No: 0%) | In patients requiring urgent clinical evaluation, consider converting to telemedicine for follow-up, according to medical evolution |
- Citation: Valencia GA, Neciosup S, Gómez HL, Benites MDP, Falcón S, Moron D, Veliz K, Maldonado M, Auqui R. Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context. World J Clin Oncol 2021; 12(1): 31-42
- URL: https://www.wjgnet.com/2218-4333/full/v12/i1/31.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i1.31